From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrew Armstrong, MD, from Duke University, Durham, NC, highlights the need for novel therapies targeting plasticity pathways in particular, in order to treat bone metastases in patients with prostate cancer. Dr Armstrong also outlines potential predictive biomarkers, including DNA defects in PARP inhibitors and androgen receptor defects.
Targeting plasticity pathways for novel therapy in prostate cancer
